Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The study participant is being asked to take part in this clinical trial, a type of research study, because the participant has Gastrointestinal (GI) symptoms following a Hematopoietic Cell Transplant (HCT). Primary Objective * To determine the safety and feasibility of FMT for treating a GvHD of the gut following HCT. * To determine the safety and feasibility of FMT for treating HCT induced gut dysfunction. Secondary Objectives * To assess the potential efficacy of FMT for treating a GvHD of the gut following HCT. * To assess the potential efficacy of FMT for treating HCT induced gut dysfunction.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 22
Healthy Volunteers: f
View:

• Age \< 22 years old.

• Received an allogeneic HCT greater than or equal to 30 days prior to enrollment

• Diagnosed with one of the following conditions:

‣ Steroid-resistant gut a GvHD (defined as GI symptoms that do not improve within 5 days after initial steroid therapy, \>/= 1mg/kg of prednisolone) OR

⁃ Steroid-dependent gut a GvHD (defined as the presence of a response to methylprednisolone 2 mg/kg/day but relapsing when an attempt was made to taper steroid treatment).

‣ OR

⁃ Current or prolonged GI dysfunction following HCT, defined as having diarrhea or loose stools \>/= 4 weeks with at least one of the following:

• Requiring NG or G-tube feeds

∙ Requiring TPN or IVF for more than 4 weeks

∙ Diagnosis of gastroparesis by GI specialist documented in the medical record

• Willing and able to provide informed assent/consent

Locations
United States
Tennessee
St. Jude Children's Research Hospital
RECRUITING
Memphis
Contact Information
Primary
Gabriela Maron, MD
referrainfo@stjude.org
866-278-5833
Time Frame
Start Date: 2025-07-07
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 10
Treatments
Experimental: Stratum A
Diagnosed with GvHD
Experimental: Stratum B
GI Dysfunction
Related Therapeutic Areas
Sponsors
Leads: St. Jude Children's Research Hospital

This content was sourced from clinicaltrials.gov